Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.43 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL27951982 | 0.82 | HSD17B10 (0.89) | HSD17B10ALDH1A1ALDH5A1ABATCYP1A2 | |
| SCHEMBL1796583 | 0.82 | MAPT (0.55) | HSD17B10ALDH1A1CES2CES1ALOX15 | |
| SCHEMBL1919 | 0.82 | — | — | |
| SCHEMBL3565290 | 0.81 | HSD17B10 (0.70) | HSD17B10ALDH1A1CES2CES1ALDH5A1 | |
| SCHEMBL17521331 | 0.81 | ALDH1A1 (0.56) | HSD17B10ALDH1A1CES2CES1ALDH5A1 | |
| Methyl Alcohol SCHEMBL28044962 | 0.80 | HSD17B10 (0.84) | HSD17B10ALDH1A1ALDH5A1ABATCYP1A2 | |
| Hydrochloric Acid SCHEMBL27964006 | 0.79 | MAPT (0.52) | HSD17B10ALDH1A1CES2CES1ALOX15 | |
| SCHEMBL8995751 | 0.79 | HSD17B10 (0.94) | HSD17B10ALDH1A1ALDH5A1ABATCYP1A2 | |
| SCHEMBL31544783 | 0.79 | HSD17B10 (0.94) | HSD17B10ALDH1A1ALDH5A1ABATCYP1A2 | |
| SCHEMBL28981622 | 0.79 | HSD17B10 (0.94) | HSD17B10ALDH1A1ALDH5A1ABATCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687639-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-30 | — | — | US | disclosed |
| EP-1613313-B1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5]-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-06 | — | — | EP | disclosed |
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | BW CONVERTING AB (SE) | 2006-11-09 | — | — | US | disclosed |
| US-7132440-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-07 | — | — | US | disclosed |
| EP-1613313-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004093873-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-`4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214857-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDKN1A, DDB1, TMBIM6 | HSD17B10 4524/4885ALDH1A1 1427/4885CES2 1968/4885 |
| US-20040214857-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, CDS2, DDB1 | HSD17B10 4680/4885ALDH1A1 1463/4885CES2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.